Annalice Gandini shared on LinkedIn:
“I am honoured to have had the opportunity to present at ESMO 2024 in Barcelone the results of our analysis on Early-Onset colon cancer, for whom I have been awarded with the prestigious ESMO Merit Travel Grant.
2973 stage III colon cancer patients were analysed from a clinical, genetic and transcriptomic point of view.
Compared to late-onset colon cancer, young patients:
– are in better general conditions
– are diagnosed in more advanced stage of disease and have a poorly differentiated hystology
– are more often CMS1, MSI, mutated in inheritance-related genes and in rare and targetable mutations (HER2, KRAS G12C)
– have the same prognosis in terms of RFS, and a possible effect of age could exist in CMS1 subgroup according to MMR status.
Stay tuned for the full manuscript!”
Source: Annalice Gandini/LinkedIn
Annalice Gandini is a fellow at Cordeliers Research Center and Medical Oncology Specialist at San Martino Polyclinic Hospital. She has particular interest in clinical and translational research, especially focused on gastrointestinal cancers.